|
시장보고서
상품코드
2003653
프란루카스트 시장 규모, 점유율 및 성장 분석 : 투약 역가별, 제형별, 환자층별, 치료 용도별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Pranlukast Market Size, Share, and Growth Analysis, By Dosage Strength (75 MG, 150 MG), By Formulation (Tablets, Inhalers), By Patient Demographics, By Therapeutic Use, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 프란루카스트 시장 규모는 2024년에 17억 달러로 평가되며, 2025년 17억 7,000만 달러에서 2033년까지 24억 6,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 4.2%로 성장할 것으로 전망되고 있습니다.
세계의 프란루카스트 시장은 만성 호흡기 질환 및 알레르기 질환의 유병률 증가에 따라 외래 진료에서 경구용 류코트리엔 수용체 길항제의 사용이 증가하고 있습니다. 이 시장에는 브랜드 및 제네릭 프란루카스트가 모두 포함되어 있으며, 특히 흡입기 사용이 어려운 경우 환자의 복약 순응도를 높이는 경구용 치료제의 이점을 크게 누리고 있습니다. 제네릭으로의 전환으로 가격 인하를 통해 지불자의 보험 적용 범위가 확대되고, 의료 제공자의 수용도가 높아지면서 특히 소아, 노인 등 환자층을 대상으로 하는 외래 진료에서 접근성이 확대되고 있습니다. 또한 AI는 화합물 선택의 효율화, 위험 감소, 새로운 투여 방법을 통한 환자 복약 순응도 강화, 시장 세분화, 제네릭 경쟁 속에서 제품 출시 최적화 등을 통해 연구개발(R&D) 및 상업화에 혁명을 일으켜 시장 성장에 기여하고 있습니다. 시장의 성장을 촉진하고 있습니다.
세계의 프란루카스트 시장의 성장 요인
천식 및 관련 알레르기성 호흡기 질환의 유병률이 증가함에 따라 프란루카스트와 같은 표적형 류코트리엔 수용체 길항제의 혜택을 받을 수 있는 환자군이 확대되고 있으며, 이 치료 분야에 대한 투자와 관심이 증가하고 있습니다. 기존 치료법으로 충분한 조절이 불가능한 경우, 의료진은 적극적으로 대체요법을 모색하고 있으며, 그 결과 다양한 작용 기전을 가진 약물에 대한 관심이 높아지고 있습니다. 이러한 높아진 임상적 요구는 연구 활동을 촉진하고, 시장 진입 노력을 지원하며, 의료진의 인지도를 높이는 데 기여하고 있으며, 이 모든 것이 세계 시장에서 플라누르카스트 관련 제품에 대한 수요가 크게 증가하고 지속적으로 성장하고 있습니다.
세계의 프란루카스트 시장 억제요인
세계의 프란루카스트 시장은 부작용 보고와 장기적인 안전성 프로파일에 대한 우려로 인해 도전에 직면해 있습니다. 이러한 문제들로 인해 처방 의사들 사이에서는 신중함이 생겨났고, 잘 알려져 있고 널리 받아들여지는 확립된 치료법을 선호하는 경향이 있습니다. 안전에 대한 고려는 임상적 의사결정에 중요한 역할을 하며, 종종 특정 환자군에서 약물의 채택을 제한할 수 있는 강화된 모니터링 및 위험 관리 전략이 필요합니다. 의료진과 환자 모두의 이러한 신중한 태도는 결과적으로 처방 동향과 시장 침투 속도를 둔화시키고 있습니다. 또한 이는 제조업체들이 플라누르카스트의 광범위한 수용을 촉진하기 위해 안전성 연구와 교육 프로그램에 더 많은 투자를 하도록 유도하는 요인으로 작용하고 있습니다.
세계의 프란루카스트 시장 동향
세계의 프란루카스트 시장에서는 환자 개개인의 프로파일에 맞게 치료법을 최적화하는 약물유전체학 및 바이오마커 관련 전략에 힘입어 정밀의료(Precision Medicine)로의 전환이 두드러지게 나타나고 있습니다. 진단 툴와 디지털 복약 순응도 프로그램의 통합을 통해 의료진은 류코트리엔 수용체 길항제로부터 가장 큰 혜택을 받을 수 있는 환자를 식별할 수 있으며, 용량 최적화 및 반응 모니터링을 촉진할 수 있습니다. 제약회사와 진단기기 제조사와의 제휴는 제품 라벨의 정교화를 촉진하고, 타겟팅된 마케팅 활동을 지원합니다. 이러한 개별화된 접근 방식은 임상 결과와 의사의 처방에 대한 확신을 높여줄 뿐만 아니라, 전문 시장 부문에서 전략적 가격 책정 및 계약 체결에 기여하는 고유한 가치 제안을 창출하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 프란루카스트 시장 규모 : 투약 역가별
세계의 프란루카스트 시장 규모 : 제형별
세계의 프란루카스트 시장 규모 : 환자층별
세계의 프란루카스트 시장 규모 : 치료 용도별
세계의 프란루카스트 시장 규모 : 유통 채널별
세계의 프란루카스트 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.04.28Global Pranlukast Market size was valued at USD 1.7 Billion in 2024 and is poised to grow from USD 1.77 Billion in 2025 to USD 2.46 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026-2033).
The global pranlukast market is significantly driven by the increasing prevalence of chronic respiratory and allergic conditions, which promote the use of oral leukotriene receptor antagonists for outpatient care. This market encompasses both branded and generic forms of pranlukast, particularly benefitting from oral therapies that enhance patient adherence, especially when inhalers are challenging to use. The shift toward generic offerings is expanding access as lower prices increase payer coverage and provider acceptance, especially in outpatient settings catering to populations such as children and the elderly. Furthermore, AI is revolutionizing R&D and commercialization by streamlining compound selection, reducing risks, enhancing patient adherence through novel delivery methods, refining market segmentation, and optimizing rollouts amidst rising generic competition, thereby propelling market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pranlukast market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Pranlukast Market Segments Analysis
Global pranlukast market is segmented by dosage strength, formulation, patient demographics, therapeutic use, distribution channel and region. Based on dosage strength, the market is segmented into 75 MG, 150 MG and 300 MG. Based on formulation, the market is segmented into Tablets, Inhalers and Others. Based on patient demographics, the market is segmented into Pediatric, Adult and Geriatric. Based on therapeutic use, the market is segmented into Asthma and Chronic Obstructive Pulmonary Disease (COPD). Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Pranlukast Market
The increasing prevalence of asthma and associated allergic respiratory conditions has broadened the patient base that stands to gain from targeted leukotriene receptor antagonists like pranlukast, driving investment and attention in this therapeutic area. Medical professionals are actively seeking alternatives when traditional treatments do not achieve adequate control, leading to a heightened interest in medications with varied mechanisms of action. This escalating clinical requirement fuels research initiatives, aids in market entry efforts, and enhances awareness among healthcare providers, all of which contribute to a significant surge in demand and ongoing growth for pranlukast-related products within the global market.
Restraints in the Global Pranlukast Market
The global pranlukast market faces challenges due to reports of adverse reactions and concerns regarding long-term safety profiles. These issues lead to a degree of caution among prescribers who may prefer established therapies that are well-known and widely accepted. Safety considerations play a significant role in clinical decision-making, often requiring enhanced monitoring or risk management strategies that can limit the drug's adoption within specific patient groups. This cautious approach from both healthcare providers and patients consequently slows down the prescribing momentum and market penetration. Additionally, it drives manufacturers to invest in further safety studies and educational programs to foster broader acceptance of pranlukast.
Market Trends of the Global Pranlukast Market
The global Pranlukast market is witnessing a significant trend towards precision medicine, driven by pharmacogenomic and biomarker-related strategies that tailor therapies to individual patient profiles. The integration of diagnostic tools and digital adherence programs empowers healthcare providers to pinpoint patients who will most benefit from leukotriene receptor antagonism, facilitating optimized dosing and response monitoring. Collaborations between pharmaceutical companies and diagnostics firms enhance the refining of product labels and support targeted marketing efforts. This personalized approach not only boosts clinical outcomes and prescribing confidence among physicians but also creates unique value propositions that contribute to strategic pricing and contracting in specialized market segments.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
- Pricing Analysis
- Patent Analysis
Global Pranlukast Market Size by Dosage Strength & CAGR (2026-2033)
- Market Overview
- 75 MG
- 150 MG
- 300 MG
Global Pranlukast Market Size by Formulation & CAGR (2026-2033)
- Market Overview
- Tablets
- Inhalers
- Others
Global Pranlukast Market Size by Patient Demographics & CAGR (2026-2033)
- Market Overview
- Pediatric
- Adult
- Geriatric
Global Pranlukast Market Size by Therapeutic Use & CAGR (2026-2033)
- Market Overview
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
Global Pranlukast Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Pranlukast Market Size & CAGR (2026-2033)
- North America (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
- US
- Canada
- Europe (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Mylan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Cadila
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GSK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
